Iambic Therapeutics (NASDAQ:IAM) Stock Rated “Buy” in New Coverage at Bank of America

Bank of America began coverage on shares of Iambic Therapeutics (NASDAQ:IAM – Get Free Report) in a report issued on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $30.00 price target on the stock. Bank of America‘s target price would suggest a potential upside of 194.99% from the stock’s previous close.

Separately, Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $24.67.

Get Our Latest Research Report on Iambic Therapeutics

Iambic Therapeutics Stock Performance

NASDAQ IAM opened at $10.17 on Monday. Iambic Therapeutics has a 52-week low of $9.60 and a 52-week high of $25.00.

Insiders Place Their Bets

In other Iambic Therapeutics news, Director Evan Lockwood Rachlin purchased 718,750 shares of the stock in a transaction on Friday, October 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director directly owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Iambic Therapeutics Company Profile

(Get Free Report)

Featured Articles

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.